Pub Date : 2024-02-23Epub Date: 2023-06-21DOI: 10.18176/jiaci.0920
P Granda, E Villamañán, S Heinz, D Laorden, D Romero, J M Añón, C Carpio, C Sobrino, V Collada, J Domínguez-Ortega, A Herrero, S Quirce, R Álvarez-Sala
{"title":"Compassionate Use of Reslizumab in a Life-threatening Asthma Exacerbation.","authors":"P Granda, E Villamañán, S Heinz, D Laorden, D Romero, J M Añón, C Carpio, C Sobrino, V Collada, J Domínguez-Ortega, A Herrero, S Quirce, R Álvarez-Sala","doi":"10.18176/jiaci.0920","DOIUrl":"10.18176/jiaci.0920","url":null,"abstract":"","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"60-61"},"PeriodicalIF":7.2,"publicationDate":"2024-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9689302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-22Epub Date: 2023-05-23DOI: 10.18176/jiaci.0915
P Andrade Garbán, A Rosado, J Macías Iglesias, M Goyanes Malumbres, M Moro Moro
{"title":"Exhaustive Diagnosis of Heat Urticaria in a Regular Clinical Practice: Report of 2 Cases.","authors":"P Andrade Garbán, A Rosado, J Macías Iglesias, M Goyanes Malumbres, M Moro Moro","doi":"10.18176/jiaci.0915","DOIUrl":"10.18176/jiaci.0915","url":null,"abstract":"","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"56-57"},"PeriodicalIF":7.2,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9558371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-22Epub Date: 2023-06-01DOI: 10.18176/jiaci.0914
K Pose, E Narváez-Fernández, A López de la Guía, L De Las Vecillas, J Domínguez-Ortega, M Lluch-Bernal, A Fiandor, R Cabañas
{"title":"A Tailored 7- to 10-Day Lenalidomide Desensitization Protocol.","authors":"K Pose, E Narváez-Fernández, A López de la Guía, L De Las Vecillas, J Domínguez-Ortega, M Lluch-Bernal, A Fiandor, R Cabañas","doi":"10.18176/jiaci.0914","DOIUrl":"10.18176/jiaci.0914","url":null,"abstract":"","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"49-50"},"PeriodicalIF":7.2,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9559795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-22Epub Date: 2023-07-05DOI: 10.18176/jiaci.0926
P Gamboa, C Galán, A Arrien, A Segurola, I Jáuregui
{"title":"Life-threatening Idiopathic Nonhistaminergic Acquired Angioedema With Response to Lanadelumab.","authors":"P Gamboa, C Galán, A Arrien, A Segurola, I Jáuregui","doi":"10.18176/jiaci.0926","DOIUrl":"10.18176/jiaci.0926","url":null,"abstract":"","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"68-70"},"PeriodicalIF":7.2,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9742357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-22Epub Date: 2023-09-20DOI: 10.18176/jiaci.0943
L Pérez de Llano, M C Muñiz Fernández, I Dávila
{"title":"Impact of the ERS/ATS 2022 Guidelines for Interpretation of Lung Function Test Results When Assessing the Response to Biologics in Asthma.","authors":"L Pérez de Llano, M C Muñiz Fernández, I Dávila","doi":"10.18176/jiaci.0943","DOIUrl":"10.18176/jiaci.0943","url":null,"abstract":"","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"73-74"},"PeriodicalIF":7.2,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41155699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-22Epub Date: 2023-06-21DOI: 10.18176/jiaci.0922
D Betancor, S Fernandez-Bravo, E Nuñez-Borque, B Gonzalez-Cano, V Esteban, C Pastor-Vargas, J Cuesta-Herranz
{"title":"Is Pru p 7 (Peamaclein) Sensitization a Predominant Cause of Cypress Pollen-Associated Peach Allergy in Spain?","authors":"D Betancor, S Fernandez-Bravo, E Nuñez-Borque, B Gonzalez-Cano, V Esteban, C Pastor-Vargas, J Cuesta-Herranz","doi":"10.18176/jiaci.0922","DOIUrl":"10.18176/jiaci.0922","url":null,"abstract":"","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"53-55"},"PeriodicalIF":7.2,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9686679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-22Epub Date: 2023-10-09DOI: 10.18176/jiaci.0949
J C Miralles-López, D Antolín-Amérigo, I García-Moguel, J Domínguez-Ortega, J Delgado-Romero, S Quirce
Asthma is one of the most common chronic diseases and is estimated to be severe in 3%-10% of affected patients. There is a need for additional biologic treatments that are highly efficacious across the spectrum of severe uncontrolled asthma. Currently available drugs inhibit 1 or 2 specific cytokines or IgE antibodies and thus only partially suppress the complex type 2 (T2) inflammatory cascade. Biologics targeting more upstream molecules in the pathophysiological pathway of asthma could treat asthma more effectively. Tezepelumab is a human monoclonal immunoglobulin G2λ antibody that targets the cytokine thymic stromal lymphopoietin (TSLP). It is the first marketed biologic against an epithelial cell-derived cytokine, preventing binding of TSLP to its receptor and reducing the immune stimuli that TSLP can trigger in different asthma endotypes. Tezepelumab reduces downstream biomarkers of inflammation, such as blood and airway eosinophils, FeNO, IgE, IL-5, and IL-13. Tezepelumab provides a clinical benefit in severe asthma, reducing the annualized asthma exacerbation rate in patients with either high or low levels of biomarkers of T2 inflammation, although the effect is greater among those with high levels. The drug has been shown to improve asthma control, quality of life, and lung function and reduce airway hyperresponsiveness. Therefore, tezepelumab can be used across the spectrum of patients with severe uncontrolled asthma, especially in T2-high patients. This review includes a positioning statement by the authors, all of whom are members of the SEAIC Asthma Committee.
{"title":"Positioning of Tezepelumab in Severe Asthma.","authors":"J C Miralles-López, D Antolín-Amérigo, I García-Moguel, J Domínguez-Ortega, J Delgado-Romero, S Quirce","doi":"10.18176/jiaci.0949","DOIUrl":"10.18176/jiaci.0949","url":null,"abstract":"<p><p>Asthma is one of the most common chronic diseases and is estimated to be severe in 3%-10% of affected patients. There is a need for additional biologic treatments that are highly efficacious across the spectrum of severe uncontrolled asthma. Currently available drugs inhibit 1 or 2 specific cytokines or IgE antibodies and thus only partially suppress the complex type 2 (T2) inflammatory cascade. Biologics targeting more upstream molecules in the pathophysiological pathway of asthma could treat asthma more effectively. Tezepelumab is a human monoclonal immunoglobulin G2λ antibody that targets the cytokine thymic stromal lymphopoietin (TSLP). It is the first marketed biologic against an epithelial cell-derived cytokine, preventing binding of TSLP to its receptor and reducing the immune stimuli that TSLP can trigger in different asthma endotypes. Tezepelumab reduces downstream biomarkers of inflammation, such as blood and airway eosinophils, FeNO, IgE, IL-5, and IL-13. Tezepelumab provides a clinical benefit in severe asthma, reducing the annualized asthma exacerbation rate in patients with either high or low levels of biomarkers of T2 inflammation, although the effect is greater among those with high levels. The drug has been shown to improve asthma control, quality of life, and lung function and reduce airway hyperresponsiveness. Therefore, tezepelumab can be used across the spectrum of patients with severe uncontrolled asthma, especially in T2-high patients. This review includes a positioning statement by the authors, all of whom are members of the SEAIC Asthma Committee.</p>","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"1-11"},"PeriodicalIF":7.2,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41172065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-22Epub Date: 2023-07-26DOI: 10.18176/jiaci.0923
B Sousa-Pinto, Y Palamarchuk, L Leemann, S Jankin, X Basagaña, J Ballester, A Bedbrook, W Czarlewski, R Almeida, T Haahtela, H Haveri, M Prass, T Henriques, R J Vieira, L Klimek, M Ollert, M H Shamji, M Jutel, S Del Giacco, M J Torres, T Zuberbier, J A Fonseca, M Sofiev, J M Anto, J Bousquet
Plant species vary under different climatic conditions and the distribution of pollen in the air. Trends in pollen distribution can be used to assess the impact of climate change on public health. In 2015, the Mobile Airways Sentinel networK for rhinitis and asthma (MASK-air®) was launched as a project of the European Innovation Partnership on Active and Healthy Ageing (EIP-on-AHA, DG Santé and DG CONNECT). This project aimed to develop a warning system to inform patients about the onset of the pollen season, namely, the System for Integrated modeLling of Atmospheric coMposition (SILAM). A global-to-meso-scale dispersion model was developed by the Finnish Meteorological Institute (FMI). It provides quantitative information on atmospheric pollution of anthropogenic and natural origins, particularly on allergenic pollens. Impact of Air Pollution on Asthma and Rhinitis (POLLAR, EIT Health) has combined MASK-air clinical data with SILAM forecasts. A new Horizon Europe grant (Climate Action to Advance HeaLthY Societies in Europe [CATALYSE]; grant agreement number 101057131), which came into force in September 2022, aims to improve our understanding of climate change and help us find ways to counteractit. One objective of this project is to develop early warning systems and predictive models to improve the effectiveness of strategies for adapting to climate change. One of the warning systems is focused on allergic rhinitis (CATALYSE Task 3.2), with a collaboration between the FMI (Finland), Porto University (Portugal), MASK-air SAS (France), ISGlobal (Spain), Hertie School (Germany), and the University of Zurich (Switzerland). It is to be implemented with the support of the European Academy of Allergy and Clinical Immunology. This paper reports the planning of CATALYSE Task 3.2.
{"title":"From MASK-air and SILAM to CATALYSE (Climate Action To Advance HeaLthY Societies in Europe).","authors":"B Sousa-Pinto, Y Palamarchuk, L Leemann, S Jankin, X Basagaña, J Ballester, A Bedbrook, W Czarlewski, R Almeida, T Haahtela, H Haveri, M Prass, T Henriques, R J Vieira, L Klimek, M Ollert, M H Shamji, M Jutel, S Del Giacco, M J Torres, T Zuberbier, J A Fonseca, M Sofiev, J M Anto, J Bousquet","doi":"10.18176/jiaci.0923","DOIUrl":"10.18176/jiaci.0923","url":null,"abstract":"<p><p>Plant species vary under different climatic conditions and the distribution of pollen in the air. Trends in pollen distribution can be used to assess the impact of climate change on public health. In 2015, the Mobile Airways Sentinel networK for rhinitis and asthma (MASK-air®) was launched as a project of the European Innovation Partnership on Active and Healthy Ageing (EIP-on-AHA, DG Santé and DG CONNECT). This project aimed to develop a warning system to inform patients about the onset of the pollen season, namely, the System for Integrated modeLling of Atmospheric coMposition (SILAM). A global-to-meso-scale dispersion model was developed by the Finnish Meteorological Institute (FMI). It provides quantitative information on atmospheric pollution of anthropogenic and natural origins, particularly on allergenic pollens. Impact of Air Pollution on Asthma and Rhinitis (POLLAR, EIT Health) has combined MASK-air clinical data with SILAM forecasts. A new Horizon Europe grant (Climate Action to Advance HeaLthY Societies in Europe [CATALYSE]; grant agreement number 101057131), which came into force in September 2022, aims to improve our understanding of climate change and help us find ways to counteractit. One objective of this project is to develop early warning systems and predictive models to improve the effectiveness of strategies for adapting to climate change. One of the warning systems is focused on allergic rhinitis (CATALYSE Task 3.2), with a collaboration between the FMI (Finland), Porto University (Portugal), MASK-air SAS (France), ISGlobal (Spain), Hertie School (Germany), and the University of Zurich (Switzerland). It is to be implemented with the support of the European Academy of Allergy and Clinical Immunology. This paper reports the planning of CATALYSE Task 3.2.</p>","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"12-19"},"PeriodicalIF":7.2,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9874300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-22Epub Date: 2023-06-09DOI: 10.18176/jiaci.0921
E Alarcón Gallardo, R Escudero Apesteguía, C Sanz Bescós
{"title":"ATAK Complex due to Amoxicillin: A Case Report.","authors":"E Alarcón Gallardo, R Escudero Apesteguía, C Sanz Bescós","doi":"10.18176/jiaci.0921","DOIUrl":"10.18176/jiaci.0921","url":null,"abstract":"","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"62-64"},"PeriodicalIF":7.2,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9950881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-22Epub Date: 2023-06-01DOI: 10.18176/jiaci.0916
M A Díaz-Palacios, R López-Salgueiro, N Catalán-Cáceres, E Ibáñez-Echevarría, R Alamar-Martínez, B Bartolomé
{"title":"Allergy to Moth Plant (Araujia sericifera) and Passion Fruit.","authors":"M A Díaz-Palacios, R López-Salgueiro, N Catalán-Cáceres, E Ibáñez-Echevarría, R Alamar-Martínez, B Bartolomé","doi":"10.18176/jiaci.0916","DOIUrl":"10.18176/jiaci.0916","url":null,"abstract":"","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"58-59"},"PeriodicalIF":7.2,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9559794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}